Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.49 Million USD | 143.93% |
| 2022 | 3.48 Million USD | -9.57% |
| 2021 | 3.84 Million USD | 3.04% |
| 2020 | 3.73 Million USD | 17.57% |
| 2019 | 3.17 Million USD | 65.02% |
| 2018 | 1.92 Million USD | 104.16% |
| 2017 | 943.03 Thousand USD | 175.3% |
| 2016 | 342.54 Thousand USD | -66.14% |
| 2015 | 1.01 Million USD | 10.54% |
| 2014 | 915.14 Thousand USD | -7.97% |
| 2013 | 994.38 Thousand USD | -7.03% |
| 2012 | 1.06 Million USD | -21.69% |
| 2011 | 1.36 Million USD | 158.19% |
| 2010 | 528.99 Thousand USD | 464.7% |
| 2009 | 93.67 Thousand USD | 29.88% |
| 2008 | 72.12 Thousand USD | -69.32% |
| 2007 | 235.06 Thousand USD | 17.33% |
| 2006 | 200.35 Thousand USD | 7.43% |
| 2005 | 186.48 Thousand USD | -57.8% |
| 2004 | 441.94 Thousand USD | 48.95% |
| 2003 | 296.7 Thousand USD | 1.1% |
| 2002 | 293.48 Thousand USD | -32.92% |
| 2001 | 437.5 Thousand USD | -5.56% |
| 2000 | 463.27 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 9.84 Million USD | 50.15% |
| 2024 Q1 | 6.55 Million USD | -22.81% |
| 2023 Q1 | 4.53 Million USD | 30.32% |
| 2023 FY | 8.49 Million USD | 143.93% |
| 2023 Q2 | 6.12 Million USD | 35.08% |
| 2023 Q4 | 8.49 Million USD | 27.68% |
| 2023 Q3 | 6.64 Million USD | 8.52% |
| 2022 Q3 | 2.87 Million USD | 36.79% |
| 2022 Q4 | 3.48 Million USD | 21.06% |
| 2022 Q1 | 2.87 Million USD | -25.28% |
| 2022 FY | 3.48 Million USD | -9.57% |
| 2022 Q2 | 2.1 Million USD | -26.92% |
| 2021 Q1 | 3.81 Million USD | 2.25% |
| 2021 Q3 | 3.46 Million USD | 11.3% |
| 2021 Q4 | 3.84 Million USD | 10.94% |
| 2021 FY | 3.84 Million USD | 3.04% |
| 2021 Q2 | 3.11 Million USD | -18.39% |
| 2020 Q1 | 3.98 Million USD | 25.39% |
| 2020 FY | 3.73 Million USD | 17.57% |
| 2020 Q4 | 3.73 Million USD | -19.79% |
| 2020 Q3 | 4.65 Million USD | 11.35% |
| 2020 Q2 | 4.18 Million USD | 4.98% |
| 2019 FY | 3.17 Million USD | 65.02% |
| 2019 Q1 | 2.68 Million USD | 39.55% |
| 2019 Q2 | 2.75 Million USD | 2.39% |
| 2019 Q3 | 2.37 Million USD | -13.52% |
| 2019 Q4 | 3.17 Million USD | 33.55% |
| 2018 Q1 | 1.06 Million USD | 13.26% |
| 2018 FY | 1.92 Million USD | 104.16% |
| 2018 Q4 | 1.92 Million USD | 16.34% |
| 2018 Q3 | 1.65 Million USD | 28.39% |
| 2018 Q2 | 1.28 Million USD | 20.69% |
| 2017 FY | 943.03 Thousand USD | 175.3% |
| 2017 Q4 | 943.03 Thousand USD | -16.56% |
| 2017 Q3 | 1.13 Million USD | 99.55% |
| 2017 Q2 | 566.37 Thousand USD | 156.29% |
| 2017 Q1 | 220.98 Thousand USD | -35.49% |
| 2016 Q4 | 342.54 Thousand USD | -60.89% |
| 2016 Q1 | 990.61 Thousand USD | -2.07% |
| 2016 Q2 | 1.12 Million USD | 13.35% |
| 2016 Q3 | 875.94 Thousand USD | -21.99% |
| 2016 FY | 342.54 Thousand USD | -66.14% |
| 2015 Q4 | 1.01 Million USD | -2.7% |
| 2015 Q1 | 907.08 Thousand USD | -0.88% |
| 2015 Q2 | 850.06 Thousand USD | -6.29% |
| 2015 FY | 1.01 Million USD | 10.54% |
| 2015 Q3 | 1.03 Million USD | 22.31% |
| 2014 Q2 | 908.05 Thousand USD | -9.88% |
| 2014 FY | 915.14 Thousand USD | -7.97% |
| 2014 Q3 | 1 Million USD | 11.04% |
| 2014 Q4 | 915.14 Thousand USD | -9.24% |
| 2014 Q1 | 1 Million USD | 1.33% |
| 2013 Q2 | 1.01 Million USD | -9.7% |
| 2013 Q3 | 963.79 Thousand USD | -5.48% |
| 2013 Q4 | 994.38 Thousand USD | 3.17% |
| 2013 FY | 994.38 Thousand USD | -7.03% |
| 2013 Q1 | 1.12 Million USD | 5.57% |
| 2012 Q4 | 1.06 Million USD | -14.35% |
| 2012 Q1 | 1.35 Million USD | -0.91% |
| 2012 Q2 | 1.29 Million USD | -4.06% |
| 2012 FY | 1.06 Million USD | -21.69% |
| 2012 Q3 | 1.24 Million USD | -3.83% |
| 2011 Q4 | 1.36 Million USD | 29.77% |
| 2011 Q3 | 1.05 Million USD | 10.16% |
| 2011 Q1 | 869.42 Thousand USD | 64.36% |
| 2011 Q2 | 955.38 Thousand USD | 9.89% |
| 2011 FY | 1.36 Million USD | 158.19% |
| 2010 FY | 528.99 Thousand USD | 464.7% |
| 2010 Q2 | 65.17 Thousand USD | -0.16% |
| 2010 Q4 | 528.99 Thousand USD | 0.42% |
| 2010 Q3 | 526.79 Thousand USD | 708.23% |
| 2010 Q1 | 65.28 Thousand USD | -30.31% |
| 2009 Q2 | 64.65 Thousand USD | -25.07% |
| 2009 Q4 | 93.67 Thousand USD | 135.24% |
| 2009 FY | 93.67 Thousand USD | 29.88% |
| 2009 Q1 | 86.28 Thousand USD | 19.64% |
| 2009 Q3 | 39.82 Thousand USD | -38.41% |
| 2008 FY | 72.12 Thousand USD | -69.32% |
| 2008 Q4 | 72.12 Thousand USD | -3.12% |
| 2008 Q3 | 74.44 Thousand USD | 29.15% |
| 2008 Q2 | 57.64 Thousand USD | -51.31% |
| 2008 Q1 | 118.38 Thousand USD | -49.64% |
| 2007 Q2 | 159.27 Thousand USD | -17.45% |
| 2007 Q1 | 192.95 Thousand USD | -3.69% |
| 2007 Q4 | 235.06 Thousand USD | 42.97% |
| 2007 FY | 235.06 Thousand USD | 17.33% |
| 2007 Q3 | 164.41 Thousand USD | 3.22% |
| 2006 Q4 | 200.35 Thousand USD | 3.82% |
| 2006 FY | 200.35 Thousand USD | 7.43% |
| 2006 Q3 | 192.97 Thousand USD | -3.22% |
| 2006 Q2 | 199.39 Thousand USD | -24.97% |
| 2006 Q1 | 265.75 Thousand USD | 42.5% |
| 2005 FY | 186.48 Thousand USD | -57.8% |
| 2005 Q4 | 186.48 Thousand USD | -4.02% |
| 2005 Q1 | 268.32 Thousand USD | -39.29% |
| 2005 Q2 | 205.17 Thousand USD | -23.54% |
| 2005 Q3 | 194.3 Thousand USD | -5.3% |
| 2004 Q1 | 318.48 Thousand USD | 7.34% |
| 2004 Q3 | 496.77 Thousand USD | 0.92% |
| 2004 Q2 | 492.26 Thousand USD | 54.56% |
| 2004 FY | 441.94 Thousand USD | 48.95% |
| 2004 Q4 | 441.94 Thousand USD | -11.04% |
| 2003 Q4 | 296.7 Thousand USD | 0.61% |
| 2003 FY | 296.7 Thousand USD | 1.1% |
| 2003 Q1 | 291.13 Thousand USD | -0.8% |
| 2003 Q2 | 287.87 Thousand USD | -1.12% |
| 2003 Q3 | 294.91 Thousand USD | 2.44% |
| 2002 Q4 | 293.48 Thousand USD | -10.23% |
| 2002 Q1 | 417.07 Thousand USD | -4.67% |
| 2002 FY | 293.48 Thousand USD | -32.92% |
| 2002 Q2 | 386.49 Thousand USD | -7.33% |
| 2002 Q3 | 326.93 Thousand USD | -15.41% |
| 2001 Q4 | 437.5 Thousand USD | 3.8% |
| 2001 Q3 | 421.5 Thousand USD | -5.39% |
| 2001 FY | 437.5 Thousand USD | -5.56% |
| 2001 Q1 | 495.62 Thousand USD | 6.98% |
| 2001 Q2 | 445.49 Thousand USD | -10.11% |
| 2000 Q4 | 463.27 Thousand USD | 7.21% |
| 2000 Q3 | 432.1 Thousand USD | 0.0% |
| 2000 FY | 463.27 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.104% |
| Embecta Corp. | 2.03 Billion USD | 99.583% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 98.2% |
| Dynavax Technologies Corporation | 375.02 Million USD | 97.736% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 98.715% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 98.794% |
| PainReform Ltd. | 2.69 Million USD | -215.516% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 94.82% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -38.291% |
| SCYNEXIS, Inc. | 55.45 Million USD | 84.688% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 7.678% |
| Cosmos Health Inc. | 30.25 Million USD | 71.934% |
| Journey Medical Corporation | 56.49 Million USD | 84.972% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -38.291% |
| Safety Shot Inc | 3.89 Million USD | -118.151% |
| Alpha Teknova, Inc. | 38.55 Million USD | 77.976% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 93.797% |
| Bright Green Corporation | 6.43 Million USD | -31.879% |
| Procaps Group, S.A. | 462.06 Million USD | 98.162% |
| Theratechnologies Inc. | 98.63 Million USD | 91.392% |
| Harrow Health, Inc. | 241.75 Million USD | 96.488% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | 3.032% |
| Biofrontera Inc. | 23.13 Million USD | 63.306% |
| DURECT Corporation | 30.4 Million USD | 72.076% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 98.258% |
| Cronos Group Inc. | 43.73 Million USD | 80.587% |
| OptiNose, Inc. | 194.33 Million USD | 95.631% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 98.961% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 82.474% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 59.527% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 95.318% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -125.086% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 83.833% |
| Radius Health, Inc. | 804.29 Million USD | 98.944% |
| Universe Pharmaceuticals INC | 13.75 Million USD | 38.27% |
| ProPhase Labs, Inc. | 42.54 Million USD | 80.043% |
| Phibro Animal Health Corporation | 725.54 Million USD | 98.83% |
| Procaps Group S.A. | 462.06 Million USD | 98.162% |
| Alvotech | 1.88 Billion USD | 99.549% |
| TherapeuticsMD, Inc. | 14.02 Million USD | 39.449% |
| Viatris Inc. | 27.21 Billion USD | 99.969% |
| Rockwell Medical, Inc. | 30.88 Million USD | 72.507% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 90.606% |
| SIGA Technologies, Inc. | 57.97 Million USD | 85.355% |
| Tilray Brands, Inc. | 892.11 Million USD | 99.048% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 96.137% |
| Shineco, Inc. | 47.6 Million USD | 82.163% |
| PetIQ, Inc. | 645.22 Million USD | 98.684% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -3767.912% |
| Incannex Healthcare Limited | 5.83 Million USD | -45.635% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.167% |
| Alimera Sciences, Inc. | 107.35 Million USD | 92.091% |
| Silver Spike Investment Corp. | 3 Million USD | -182.093% |
| Assertio Holdings, Inc. | 148.41 Million USD | 94.279% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -347.821% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 60.168% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -20.844% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 95.103% |
| Hempacco Co., Inc. | 18.82 Million USD | 54.891% |
| Talphera, Inc. | 6.29 Million USD | -34.985% |
| Alvotech | 1.88 Billion USD | 99.549% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 95.081% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 98.983% |
| Currenc Group, Inc. | 177.67 Million USD | 95.221% |
| Kamada Ltd. | 109.96 Million USD | 92.279% |
| Indivior PLC | 1.95 Billion USD | 99.565% |
| Evoke Pharma, Inc. | 9.64 Million USD | 11.998% |
| Flora Growth Corp. | 17.22 Million USD | 50.7% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 0.0% |
| Evolus, Inc. | 209.68 Million USD | 95.951% |
| HUTCHMED (China) Limited | 536.38 Million USD | 98.417% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 99.028% |
| Akanda Corp. | 12.66 Million USD | 32.981% |